Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder

NCT05525637
clinicaltrials.gov
Phase
Phase 3
clinicaltrials.gov
Recruitment status
Completed
clinicaltrials.gov
Participants
1,037
clinicaltrials.gov
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
clinicaltrials.gov
Start date
2021-12-17
clinicaltrials.gov
Number of sites
83
clinicaltrials.gov

Summary
The main purpose of this study is to assess efficacy and safety of YZJ-1139 in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.
clinicaltrials.gov
Short title
Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder
clinicaltrials.gov
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of YZJ-1139 Tablets in the Treatment of Insomnia Disorder
clinicaltrials.gov

Control arm
Placebo
clinicaltrials.gov
Registry reports results
No
clinicaltrials.gov
Listing at source
Listed
clinicaltrials.gov
Recruitment status
Completed
clinicaltrials.gov
Phase
Phase 3
clinicaltrials.gov
Study type
Interventional
clinicaltrials.gov

Completion date
2023-09-27
clinicaltrials.gov
First posted
2022-09-01
clinicaltrials.gov
Registry last updated
2026-06-30
clinicaltrials.gov
Primary completion date
2023-07-07
clinicaltrials.gov
Start date
2021-12-17
clinicaltrials.gov

Actual participants
1,037
clinicaltrials.gov
Participants
1,037
clinicaltrials.gov
Participant count basis
Actual
clinicaltrials.gov
Protocol amendments
1
clinicaltrials.gov
Number of sites
83
clinicaltrials.gov

Registry sponsor category
Industry
clinicaltrials.gov
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
clinicaltrials.gov
Source registry
ClinicalTrials.gov
clinicaltrials.gov

Registry ID
NCT05525637
clinicaltrials.gov
ClinicalTrials.gov ID
NCT05525637
clinicaltrials.gov
Registry record
Open registry record
clinicaltrials.gov

Allocation
Randomised
Model
Parallel groups
Purpose
Treatment
Masking
Double masking
Masked roles
Participants, Investigators
Sources for study design
clinicaltrials.gov

  1. Change from baseline in the subjective sleep efficiency (sSE) after 14 days of treatment

    Timeframe: from baseline to week 2

    Subjective Sleep efficiency variation assessed by the sleep diary questionnaire at 14 days of treatment from baseline. A positive change from baseline indicates an increase in the subjective Sleep efficiency. A negative change from baseline indicates a decrease in subjective Sleep efficiency

  2. Change from baseline in the sleep efficiency (SE) after 14 days of treatment

    Timeframe: from baseline to day 14

    Sleep efficiency variation assessed by polysomnography at 14 days of treatment from baseline. A positive change from baseline indicates an increase in the Sleep efficiency. A negative change from baseline indicates a decrease in Sleep efficiency

  1. Change from baseline in the subjective sleep efficiency (sSE) after 7 days of treatment

    Timeframe: Baseline, week 1

    sSE is self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

  2. Changes from baseline in the Subjective time to sleep onset (sTSO) after 14 days of treatment for subjects entering the second treatment phase

    Timeframe: Baseline, week 1, week 2

    sTSO are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

  3. Changes from baseline in the Subjective wake after sleep onset (sWASO) after 14 days of treatment for subjects entering the second treatment phase

    Timeframe: Baseline, week 1, week 2

    sWASO are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

  4. Changes from baseline in the Subjective total sleep time (sTST) after 14 days of treatment for subjects entering the second treatment phase

    Timeframe: Baseline, week 1, week 2

    sTST are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

  5. Changes from baseline in the Subjective number of awakenings (sNAW) after 14 days of treatment for subjects entering the second treatment phase

    Timeframe: Baseline, week 1, week 2

    sNAW are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

  6. Changes from baseline in the SE after 2 days of treatment

    Timeframe: Baseline, Day1/Day2

    SE assessed by polysomnography at 2 days of treatment from baseline. A positive change from baseline indicates an increase in the Sleep efficiency. A negative change from baseline indicates a decrease in Sleep efficiency

  7. Latency to persistent sleep (LPS) after 2 and 14 days of treatment

    Timeframe: Baseline, Day1/Day2, Day13/Day14

    LPS assessed by polysomnography at 2 and 14 days of treatment from baseline. A positive change from baseline indicates an increase in the Sleep efficiency. A negative change from baseline indicates a decrease in Sleep efficiency

  8. Wake after sleep onset (WASO) after 2 and 14 days of treatment

    Timeframe: Baseline, Day1/Day2, Day13/Day14

    WASO assessed by polysomnography at 2 and 14 days of treatment from baseline. A positive change from baseline indicates an increase in the Sleep efficiency. A negative change from baseline indicates a decrease in Sleep efficiency

  9. Total sleep time (TST) after 2 and 14 days of treatment

    Timeframe: Baseline, Day1/Day2, Day13/Day14

    TST assessed by polysomnography at 2 and 14 days of treatment from baseline. A positive change from baseline indicates an increase in the Sleep efficiency. A negative change from baseline indicates a decrease in Sleep efficiency

  10. Sleep structure (wakefulness, N1, N2, N3, rapid eye movement sleep [REM], non-rapid eye movement sleep [NREM], REM latency, number of awakenings [NAW], arousal index for REM and NREM) after 2 and 14 days of treatment

    Timeframe: Baseline, Day1/Day2, Day13/Day14

    Sleep structure assessed by polysomnography at 2 and 14 days of treatment from baseline.

  11. Change from baseline in the mean subjective sleep quality score after 7 and 14 days of treatment for subjects

    Timeframe: Baseline, Week 1, Week 2

    Subjective sleep quality score is a self-report assessment of participant perception of the effects of a medication on their sleep. Higher score indicated severe insomnia problem.

  12. Percentage of Participants on each scale of Global Impression of Insomnia (PGI-I) each Item at 14 days of treatment

    Timeframe: Day 14

    The PGI-I was a self-report assessment of participant perception of the effects of a medication on their sleep. The PGI-I had 3 items related to study medication effects (a) helped/worsened sleep, (b) decreased/increased time to fall asleep, (c) increased/decreased total sleep time, and 1 item related to perceived appropriateness of study medication strength. The first 3 items were answered on a 3-point scale (1=positive medication effect, 2=neutral medication effect, 3=negative medication effect) and the last item on a different 3 point scale (medication: 1=too strong, 2=just right, 3=too weak)

  13. Changes from baseline in the sSE after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    Timeframe: Baseline, Day 30, Day 90, and Day 180

    sSE are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

  14. Changes from baseline in the sTSO after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    Timeframe: Baseline, Day 30, Day 90, and Day 180

    sTSO are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

  15. Changes from baseline in the sWASO after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    Timeframe: Baseline, Day 30, Day 90, and Day 180

    sWASO are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

  16. Changes from baseline in the sTST after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    Timeframe: Baseline, Day 30, Day 90, and Day 180

    sTST are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

  17. Changes from baseline in the sNAW after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    Timeframe: Baseline, Day 30, Day 90, and Day 180

    sNAW are self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

  18. Change from baseline in the mean subjective sleep quality score after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    Timeframe: Baseline, Day 30, Day 90, and Day 180

    Subjective sleep quality score is a self-report assessment of participant perception of the effects of a medication on their sleep. Higher score indicated severe insomnia problem.

  19. Change from baseline in the Insomnia Severity Index (ISI) score after 30, 90 and 180 days of treatment for subjects entering the second treatment phase

    Timeframe: Baseline, Day 30, Day 90, and Day 180

    ISI is a self-report questionnaire assessing the nature, severity, and impact of insomnia. Higher score indicated severe insomnia problem.

  20. Percentage of Participants who enter the second treatment phase on each scale of Patient Global Impressions - ImprovementGlobal Impression of Insomnia (PGI-I) each Item at 30, 90 and 180 days of treatment

    Timeframe: Day 30, Day 90, and Day 180

    The PGI-I was a self-report assessment of participant perception of the effects of a medication on their sleep. The PGI-I had 3 items related to study medication effects (a) helped/worsened sleep, (b) decreased/increased time to fall asleep, (c) increased/decreased total sleep time, and 1 item related to perceived appropriateness of study medication strength. The first 3 items were answered on a 3-point scale (1=positive medication effect, 2=neutral medication effect, 3=negative medication effect) and the last item on a different 3 point scale (medication: 1=too strong, 2=just right, 3=too weak).

Sources for outcomes
clinicaltrials.gov

Sex
All
Age groups
Adults, Older adults
Minimum age
18 Years
Maximum age
65 Years
Healthy volunteers
No

- Subjects who meet all of the following criteria may be enrolled in the study:

  1. Aged ≥ 18 to < 65 years.

  2. Meet the clinical diagnostic criteria for insomnia disorder as defined in International Classification of Sleep Disorders, 3rd Edition (ICSD-3) criteria.

  3. sTSO ≥ 30 min for at least 3 nights per week and/or sWASO ≥ 60 min for at least 3 nights per week within 28 days (4 weeks) prior to screening.

  4. During the run-in period or on Day 1 of the treatment period, sTSO ≥ 30 min for at least 3 nights in the last 7 sleep diaries and/or sWASO ≥ 60 min for at least 3 nights out of 7 nights as confirmed by the sleep diary prior to Polysomnography (PSG) monitoring.

  5. PSG results for 2 consecutive nights during the run-in period should meet the following conditions:

    • The mean LPS of 2 nights is ≥ 30 min, with the LPS ≥ 20 min for any night;
    • And/or the mean WASO of 2 nights is ≥ 60 min, with neither night < 45 min;
    • The mean SE of 2 nights is ≤ 85%, with the SE ≤ 87.5% for both nights.

  6. ISI score ≥ 15 at screening and on Day 1 of the treatment period.

  7. Agree to follow the habitual bedtime between 9 p.m. and 1 a.m., wake up between 5 a.m. and 10 a.m. every day, and stay in bed for 6.5 to 9 hours per night during the study.

  8. Have a bedtime between 9 p.m. and 1 a.m., wake up between 5 a.m. and 10 a.m., and stay in bed for 6.5 to 9 hours for at least 5 days in the last 7 sleep diaries as confirmed by the sleep diary prior to PSG monitoring during the run-in period or on Day 1 of the treatment period.

  9. Female subjects are confirmed to be non-pregnant at screening; both men of reproductive potential and women of childbearing potential should agree to use medically acceptable and effective contraception throughout the study and within 3 months after the end of the study.

  10. Understand the study procedures and contents, voluntarily participate in the clinical study and sign the written Informed Consent Form (ICF), have good compliance during participation in the study, and are willing to attend the visits.

  • Subjects who meet any of the following criteria should be excluded from this study:

    1. Depression: Hamilton Depression Scale (HAMD) score ≥ 18; anxiety: Hamilton Anxiety Scale (HAMA) score ≥ 14.
    2. Suicidal ideation with or without plan at screening or within 6 months prior to screening (score ≥ 3 on item 3 [suicide] of HAMD, or select "Yes" on item 3, 4 or 5 of suicidal ideation subscale of Columbia-Suicide Severity Rating Scale (C-SSRS)), or have any suicidal behavior in the past 10 years (as assessed by the suicidal ideation subscale of C-SSRS).
    3. Apnea-hypopnea index (AHI) and/or periodic limb movement index (PLMI) > 10 times/hour detected by PSG monitoring during the run-in period.
    4. Repeat electrocardiogram (ECG) at screening shows QTcF interval prolongation (QTcF > 450 ms) (the ECG should be repeated 2 more times only if the initial ECG shows QTcF interval > 450 ms).
    5. Have serious endocrine diseases, hematological diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, liver and kidney diseases, autoimmune diseases, impaired respiratory function or other related diseases, or have other medical history that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
    6. Have insomnia disorder due to other causes such as chronic pain, headache, eczema, neurodermatitis, allergic rhinitis, and serious dermatitis (difficulty sleeping due to physical reasons, difficulty falling asleep due to medical reasons).
    7. Previous history of nervous system disorders such as epilepsy, schizophrenia, bipolar mental disorder, neurodevelopmental retardation, and cognitive disorder, or previous history of other mental illness that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
    8. Previous history of sleep-related respiratory disorders including obstructive sleep apnea (with or without continuous positive airway pressure (CPAP) therapy), periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disturbances, narcolepsy or other sleep disorders: subjects with restless legs syndrome which is diagnosed by relevant diagnostic and treatment guidelines should be excluded.
    9. Have previous complex sleep behaviors, such as sleep driving, sleep eating, and sleep phone calls.
    10. Plan to undergo surgery during the study.
    11. Have received any hypnotics, antidepressants, antipsychotic drugs, anticholinergics, memory-enhancing drugs, antihistamines, centrally acting analgesics, centrally acting muscle relaxants, central nervous system stimulants, cytochrome P450 3A (CYP3A) inducers, CYP3A inhibitors, traditional Chinese medicines and traditional Chinese medicinal products with sleep-improving effects, or any other therapies for insomnia disorder within 1 week prior to the run-in period or within 5 half-lives of the investigational product, whichever is longer.
    12. History of drug taking or addiction, which is known through questioning.
    13. Have any lifestyle that interferes with the study process or may interfere with sleep: for example, there will be travels across 3 or more time zones (mainland China is considered as 1 time zone) within the next 2 weeks or during the study period, or there will be shift work (night and daytime shift).
    14. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2 × the upper limit of normal (ULN), or Creatinine (Cr) > 1.5 × ULN.
    15. Hyperthyroidism.
    16. History of alcohol abuse (defined as regular daily alcohol consumption exceeding the following criteria: approximately 720 mL of beer, or 240 mL of wine, or 60 mL of liquor) within the past 2 years.
    17. History of drug abuse within the past 2 years, or positive urine drug screening for any indicator.
    18. Regular daily consumption of excessive tea and coffee drinks (defined as consumption of > 4 cups of caffeinated beverages or > 400 mg of caffeine per day), or daily habituation to drinking caffeinated beverages beyond 18:00.
    19. Have nocturia increased caused by urinary tract infection, urinary tract injury or prostatic disorder.
    20. Have positive infectious disease screening for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb) and human immunodeficiency virus (HIV) antibody at screening.
    21. Unable to avoid vaccination within 1 month prior to screening or during the first treatment phase.
    22. Have participated in clinical studies of other drugs within the past 1 month or 5 half-lives (whichever is longer), or plan to participate in other studies simultaneously during participation in this study.
    23. Pregnant or lactating women.
    24. History of allergy to the investigational product or its components.
    25. Have prior participation in clinical studies of YZJ-1139 Tablets.
    26. Have other conditions that make the subject unsuitable for participation in the clinical study in the opinion of the investigator.
Sources for eligibility
clinicaltrials.gov

  • Beijing Chao-Yang Hospital, Capital Medical UniversityBeijing, China
  • Beijing Hui Long Guan Hospital, Capital Medical UniversityBeijing, China
  • Beijing Tiantan Hospital, Capital Medical UniversityBeijing, China
  • Beijing Tsinghua Changgung HospitalBeijing, China
  • China-Japan Friendship HospitalBeijing, China
  • Peking University First HospitalBeijing, China
  • Peking University People's HospitalBeijing, China
  • Xuanwu Hospital Capital Medical UniversityBeijing, China
  • The First affiliated hospital of bengbu medical collegeBengbu, China
  • Binzhou Medical University HospitalBinzhou, China
  • The First Bethune Hospital Of Jilin UniversityChangchun, China
  • The First Hospital of ChangShaChangsha, China
  • The Second XiangYa Hospital Of Central UniversityChangsha, China
  • The Secong People's Hospital Of HuNan ProvinceChangsha, China
  • Xiangya Hospital Central South UniversityChangsha, China
  • The Fourth People's Hospital Of ChengDuChengdu, China
  • Army Medical Center of PLAChongqing, China
  • ChongQing Eleventh People's HospitalChongqing, China
  • ChongQing Mental Health CenterChongqing, China
  • ChongQing Traditional Chinese Medical HospitalChongqing, China
  • ChongQing University Three Gorges HospitalChongqing, China
  • People's Hospital Of DeYang CityDeyang, China
  • The First Affiliated Hospital Of FuJan Medical UniversityFuzhou, China
  • Guangdong Provincial People's HospitalGuangzhou, China
  • Nanfang Hospital Southern Medical UniversityGuangzhou, China

And 58 more, listed on the interactive page.

Sources for sites
clinicaltrials.gov

Related records

Drugs (1)

Lead sponsors (1)

Conditions (1)